

February 22, 2019

To whom it may concern,

Company: Japan Lifeline Co., Ltd.
Representative: Keisuke Suzuki, President and CEO
(Code: 7575 TSE 1st Section)
Contact person: Shogo Takahashi, Executive Vice President,
Corporate Administration Department
(TEL. +81-3-6711-5200)

**Announcement of the Regulatory Approval
For “Ovation Abdominal Stent Graft”**

Japan Lifeline Co., Ltd. ("JLL") received regulatory approval for the stent graft for the treatment of abdominal aortic aneurysms (AAA) – “Ovation Abdominal Stent Graft (“Ovation”)”, manufactured by Endologix, Inc. (the United States) on February 21, 2019.


Ovation’s unique stent graft design with nitinol stent and PTFE graft realized reduction of its outer diameter profile upon delivery and also made it highly flexible, and its delivery system has the lowest profile (14 Fr) amongst any commercially available devices. These features enhance deliverability of the stent graft through narrow or tortuous anatomies.

Ovation also has a unique design for fixation and sealing. When fixing the stent graft to the vessel wall, the graft’s O-rings filled with polymer conforms to the vessel wall irregularities. This fixation technology with O-rings provides customized, circumferential seal for various anatomies and avoids blood flow into the aneurysm sac and expansion of the diameter of the blood vessel over a long period of time. Clinical trials from various countries have also confirmed the durability of the sealing effect and the suppression of the expansion of blood vessel diameter at 60 months after surgery.

As described above, Ovation is a device with novel technologies; therefore, JLL is aiming to apply insurance in the new category. The launch is expected to be after the application of insurance.

JLL has sold AFX Endovascular AAA Stent Graft System, a stent graft manufactured by Endologix, for treatment of abdominal aortic aneurysms, and JLL has already received high praise from medical professionals. By adding Ovation to the product lineup, JLL expects to expand the application to cases that have been difficult to handle with AFX Endovascular AAA Stent Graft System. Therefore, JLL intends to further gain market share.

JLL has a wide range of product lineup for the treatment of aortic diseases, which includes self-manufactured vascular grafts and open stent grafts for open-heart surgeries, and also minimally invasive thoracic and abdominal stent grafts from overseas manufacturers. The company continuously provides excellent medical devices that meet various needs of patients and medical professionals.



Ovation Abdominal Stent Graft

About Endologix

Endologix, Inc. is headquartered in Irvine, California in the United States and conducts research and development into endovascular stent grafts, which are advanced and minimally invasive treatment devices for abdominal aortic aneurysms. The Company has a product portfolio with novel technologies, such as “AFX Endovascular AAA Stent Graft System”, “Ovation Abdominal Stent Graft” and “Nellix EndoVascular Aneurysm Sealing System”.